ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KROS vs SLGL // EV/EBITDA & P/E VALUATION

Keros Therapeutics Inc. (NASDAQ) VS. Sol-Gel Technologies Ltd. (NASDAQ) • 15-METRIC TALLY: KROS 6 — SLGL 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KROS VS. SLGL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KROS SLGL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 KROS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — 0.12% — TIE /fcf-yield <GO>
Operating Margin 27.70% -38.90% +66.60 KROS /operating-margins <GO>
Net Profit Margin 35.70% -31.60% +67.30 KROS /net-margins <GO>
Revenue Growth (YoY) 180.00% 68.00% +112.00 KROS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.31 8.54 -4.23 SLGL /balance-sheet <GO>
Piotroski F-Score Quality 8/9 6/9 +2.00 KROS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.6 41.5 -0.95 SLGL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $225.2M $224.8M $444.1K KROS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KROS REV SLGL REV KROS GROSS % SLGL GROSS % KROS FCF SLGL FCF
FY 2025 $244.1M $19.4M — — $106.0M $275.0K
FY 2024 $3.5M $11.5M — — -$162.8M -$13.9M
FY 2023 $151.0K $1.6M — — -$124.5M -$17.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KROS // BETA —
SLGL // BETA —